ANGel will provide new hope to countless patients suffering from hard-to-treat cancers and contribute to the realization of humanity's long-standing dream of conquering cancer. Furthermore, OncoLab plans to create value through various business models based on ANGel, offering attractive investment opportunities for investors.
In-House Development and Commercialization
-
In-House Development and Commercialization
OncoLab is pursuing a model to independently develop and commercialize cancer therapeutics using ANGel platform. In particular, the focus will be on developing treatments for triple-negative breast cancer and prostate cancer, with plans to expand into various cancers and immuno-oncology applications in the future.
-
Technology Transfer
Our company is aiming to transfer this technology to global pharmaceutical companies, generating royalties and technical fees.
-
Collaborative Research and Development
We will promote collaborative research and development utilizing ANGel platform with other biotech companies and research institutions. This will create synergies in the field of cancer treatment and uncover new technologies and business opportunities.
Investment Value of ANGel
-
High Market Potential
The market for hard-to-treat cancer therapies is rapidly growing, and it has the potential to provide groundbreaking therapeutic solutions in this market.
-
Innovative Technology
It is an innovative platform technology that overcomes the limitations of existing immuno-oncology drugs, offering excellent delivery, efficacy, and sustainability.
-
Global Competitiveness
It is receiving significant attention from global pharmaceutical companies, with the potential for market entry through technology transfer.
-
Experienced Management Team
OncoLab is led by CEO Jongseong Kim, who has over 20 years of experience in nanogel research and commercialization, along with a management team of skilled professionals.
-
Strong Partnerships
OncoLab collaborates with outstanding researchers, including those from Harvard Medical School's Springer Lab and Professor Lyon, and has established partnerships with domestic and international specialized organizations for GMP and GLP certification.